-
Marchés
-
Actions
Sustainable finance2025 Euronext ESG Trends ReportLire la suiteA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLire la suiteInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fonds
-
Obligations
European Defence BondsGroupe BPCE lists the first bondLire la suiteFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Produits Structurés
-
Dérivés
Where European Government Bonds Meet the FutureFixed Income derivativesLire la suiteTrade mini bond futures on main European government bonds
-
Marchandises
- Vue d'ensemble
- Vue d'ensemble
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Règlement livraison
- Spécifications et dispositions
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLire la suiteEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLire la suiteJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Adocia
Identification
Instrument name
ADOCIA
Symbole
ADOC
Code ISIN
FR0011184241
Exchange / Market
Euronext
Trading location
Paris
Famille de produits
Stocks
ICB
Biotechnology
Description de l'activité
Adocia est spécialisé dans la recherche et le développement de produits biothérapeutiques destinés à la régénération des tissus et au traitement de maladies chroniques.
A fin juin 2011, le groupe dispose d’un portefeuille de 4 produits en développement clinique (dont 2 en phase II ; PDGF-BB pour le traitement des ulcères du pied diabétique et HinsBet, insuline humaine à action rapide pour le traitement du diabète).
Site internet
www.adocia.com
Operation
Date de l'IPO
lun 20/02/2012
IPO type
Introduction par offre publique
Type d'IPO
Initial Public offering
Catégorie
IPO
Operation calendar
LISTING DATE: 14/02/2012
TRADING DATE: 20/02/2012
Price range
Fourchette de prix indicative : 13,00 EUR - 15,88 EUR par action (le "Prix de l'Offre")